Stryker Co. (NYSE:SYK) VP M Kathryn Fink Sells 2,121 Shares of Stock

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

M Kathryn Fink also recently made the following trade(s):

• On Tuesday, September 17th, M Kathryn Fink sold 7,347 shares of Stryker stock. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06.

Stryker Stock Performance

Shares of SYK opened at $364.00 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $374.63. The company has a 50-day simple moving average of $343.60 and a 200-day simple moving average of $342.61. The company has a market capitalization of $138.71 billion, a PE ratio of 41.55, a P/E/G ratio of 2.87 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $2.54 earnings per share. Equities research analysts predict that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.88%. Stryker’s payout ratio is 36.53%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SYK. Piper Sandler reiterated an “overweight” rating and set a $380.00 price target on shares of Stryker in a research note on Tuesday, September 10th. BTIG Research increased their target price on shares of Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Morgan Stanley boosted their price target on Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Barclays increased their price objective on Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, UBS Group boosted their target price on Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $378.58.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Burkett Financial Services LLC acquired a new stake in Stryker in the 4th quarter valued at about $25,000. Centennial Bank AR grew its position in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. Central Pacific Bank Trust Division purchased a new position in shares of Stryker during the 1st quarter worth approximately $39,000. DSM Capital Partners LLC acquired a new position in shares of Stryker during the 4th quarter worth approximately $34,000. Finally, Accent Capital Management LLC purchased a new stake in Stryker in the 4th quarter valued at approximately $60,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.